Age-related Marrow Adipogenesis Is Linked to Increased Expression of RANKL*

Sunao Takeshita1, Toshio Fumoto‡, Yoshinori Naoe§, and Kyoji Ikeda†1

From the Departments of ‡1Bone and Joint Disease and §5Mechanism of Aging, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan

Background: The osteoclastogenic cytokine RANKL is expressed in various cell types, including osteoblasts, osteocytes, and lymphocytes.

Results: RANKL expression is induced during adipogenesis through the action of C/EBPβ and/or C/EBPδ, and RANKL-positive preadipocytes increase in aging marrow along with down-regulation of osteoprotegerin.

Conclusion: Adipogenesis is linked to osteoclastogenesis through RANKL expression.

Significance: Increased marrow preadipocytes with aging may contribute to osteoporosis.

With advancing age bone marrow is progressively replaced with adipose tissue, accompanied by a concomitant decline in bone mass and strength. The mechanism underlying the increase in marrow fat and bone destruction remains elusive. We found that on the way of adipogenic differentiation of marrow stromal cells, receptor activator for NF-κB ligand (Rankl) expression was induced, concomitantly with a down-regulation of osteoprotegerin, which prompted us to hypothesize that cells at a preadipocyte stage express RANKL. This concept was supported by the findings that the early adipogenic transcription factors C/EBPβ and C/EBPδ, but not the late factor peroxisome proliferator-activated receptor γ, bind to the Rankl promoter and stimulate Rankl gene transcription. In fact, when cells isolated from the bone marrow of aging mice were analyzed by flow cytometry, we found that cells expressing the pre-adipocyte marker Pref-1 were RANKL-positive, and the number of these cells was increased with aging, with concomitant down-regulation of osteoprotegerin, and most importantly, that these RANKL+/Pref-1+ marrow cells were capable of generating osteoclasts from bone marrow macrophages. Thus, the capacity of cells at a pre-adipocyte stage to express RANKL via C/EBPβ and C/EBPδ and to support osteoclastogenesis may account partly for the co-progression of fatty marrow and bone destruction with aging.

The number and size of adipocytes in the bone marrow increase along with aging (1, 2). Clinical as well as experimental studies have shown that an increase in marrow adipocytes is seen in association with the conditions that lead to bone loss or osteoporosis, such as aging (3–6), physical inactivity (7), long term glucocorticoid use (8), and ovariectomy (9, 10). Osteoporosis and obesity, two disorders of body composition, have been increasing in prevalence, and investigation into the fat-bone connection is actively being pursued at both clinical and molecular levels (11). Increased adiposity with aging has been studied mainly from the aspect of an imbalance between adipogenesis and osteoblastogenesis (12). Adipocytes and osteoblasts are both derived from mesenchymal stem cells, and skeletal aging is characterized by decreased osteoblastogenesis and increased adipogenesis (2).

The coexistence of increased adipocytes and the progression of bone destruction with aging also suggest a mechanistic link between adipogenesis and osteoclastogenesis. There have been a couple of reports on the potential role of adipocytic cells in supporting osteoclast formation in vitro (13–15). These reports were performed using established cell lines, and did not provide the mechanism by which adipocytes regulate osteoclastogenesis, especially, the involvement of receptor activator for NF-κB ligand (RANKL)2 and its regulation during adipogenesis. Previously, we observed that bone with targeted ablation of osteocytes is characterized by fatty marrow and elevated bone resorption, mimicking the aging skeleton (16). Most strikingly, bone marrow cultures from osteocyte-ablated mice resulted in the formation of colonies of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts, without the addition of osteoclastogenic cytokines or hormones, such as RANKL and 1,25-(OH)2D3, and the osteoclasts generated under adipogenic conditions survived more than 11 weeks (16). These observations pointed to a mechanistic link between adipogenesis and osteoclastogenesis, and prompted the present study on the potential of bone marrow preadipocytes, especially those from aged mice, to support osteoclastogenesis.

* This work was supported in part by Grant-in-aid for Scientific Research C 18590359 (to S. T.) and a Grant-in-aid for Scientific Research on Innovative Areas 22118007 (to K. I.) from the Ministry of Education, Science of Japan, a grant from the program Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) of Japan (06-31) (to K. I.), and grants from Ono Foundation (to S. T.), Daiko Foundation (to K. I.), and Tokyo Biochemistry Research Foundation (to K. I.).
1 To whom correspondence should be addressed: 35 Gengo, Morioka, Obu, Aichi 474-8511, Japan. Tel.: 81-562-44-5651 (ext. 5047); Fax: 81-562-44-6595; E-mail: sunao@ncgg.go.jp.
2 The abbreviations used are: RANKL, receptor activator for NF-κB ligand; C/EBP, C/EBPα enhancer-binding protein; Dex, dexamethasone; IBMX, 3-isobutyl-1-methylxanthine; OPG, osteoprotegerin; TRAP, tartrate-resistant acid phosphatase; PE, phycocerythrin; PPARγ, peroxisome proliferator-activated receptor γ; TZD, troglitazone; BADGE, bisphenol A diglycidyl ether.
**RANKL as an Adipokine**

**EXPERIMENTAL PROCEDURES**

*Reagents and Antibodies—* Ascorbic acid, β-glycerophosphate, dexamethasone (Dex), and 3-isobutyl-1-methylxanthine (IBMX), and PPARγ antagonist bisphenol A diglycidyl ether (BADGE) were purchased from Sigma, and PPARγ agonist troglitazone (TZD) from Calbiochem (La Jolla, CA). Recombinant OPG was purchased from R&D Systems, Inc. (Minneapolis, MN).

Polyclonal antibodies against C/EBPβ and C/EBPδ were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Cell Signaling Technology, Inc. (Danvers, MA), respectively. FITC-conjugated rat monoclonal antibody against mouse Pref-1 and rat IgG1 isotype control were purchased from MBL Medical & Biological Laboratories, Co., Ltd. (Nagoya, Japan). Streptavidin-APC, biotin-conjugated rat IgG1 isotype control were purchased from BioLegend (San Diego, CA), and PE-conjugated rat monoclonal antibodies against mouse Pref-1 and rat IgG1 isotype control were purchased from BioLegend (San Diego, CA).

*Cell Culture and Staining—* Mouse fibroblastic cell line NIH3T3, mouse preadipocytic cell line 3T3-L1, and human embryonic kidney cell line 293T were purchased from DS Pharma Biomedical Co., Ltd. (Suita, Japan). The mouse calvaria-derived stromal cell line MC3T3-G2/PA6 (PA6) and bone marrow stromal cell line ST2 were obtained from Riken Bioresource Center (Tsukuba, Japan).

Primary mouse whole bone marrow cells, bone marrow stromal cells, and bone marrow macrophages were prepared as described (16–18). Whole bone marrow cells were prepared from 2-month-old to 2-year-old C57BL/6 mice (Clea Japan Inc., Shizuoka, Japan) and were cultured as described previously (16). In brief, cells were seeded in αMEM containing 10% FBS in a 6-well plate at 2–6 × 10⁶ cells/well. After 3 to 8 days, the medium was changed to osteogenic media with 10% FBS/ αMEM containing ascorbic acid (50 μg/ml) and β-glycerophosphate (10 mM) or adipogenic media with 10% FBS/αMEM containing dexamethasone (0.5 μM) and IBMX (0.5 mM), respectively. The media were changed every 3 days, and after 5 to 14 days cells were stained with hematoxylin/eosin (H&E), alkaline phosphatase, or TRAP. Alkaline phosphatase staining was performed using an alkaline phosphatase staining kit (Sigma). For TRAP staining, cultured cells were fixed with 10% formalin for 5 min and then with ethanol/acetone (50:50, v/v) for 1 min at room temperature, and incubated in acetate buffer (pH 4.8) containing naphtol AS-MX phosphate (Sigma), fast red violet LB salt (Sigma), and 50 mmol/liter of sodium tartrate. Resorption pit assay was performed, as described previously (19).

Briefly, bone marrow cells were cultured in adipogenic media, or osteoclastogenic media containing RANKL (100 ng/ml) and M-CSF (100 ng/ml) as a control, on dentin slices. After osteoclasts formed, dentin slices were harvested and cells were removed from the dentin with 1 M sodium hydrate. After washing with distilled water, dentin was stained with Coomassie Brilliant Blue and the stained resorption pits were analyzed with light microscopy. To quantitatively assess resorbing activity per osteoclast, five to six areas of the dentin slices were randomly selected and the areas of osteoclasts stained by TRAP and the resorption lacunae stained by Coomassie Brilliant Blue were determined with the NIH Image program (rsb.info.nih.gov/.nih-image/).

**RNA Isolation and RT-PCR**—Total RNA was extracted from cells using TRIzol reagent (Invitrogen) and used for RT-PCR.
analysis. The primers used for RT-PCR are summarized in Tables 1 and 2. Quantitative RT-PCR was performed using the power SYBR Green PCR master mix on a 7900 fast real-time PCR system (Applied Biosystems).

**Retroviral Expression**—The retroviral vector pMX-puro (a gift from Dr. T. Kitamura of the University of Tokyo) along with Cebpb, Cebpd (gifts from Dr. S. Akira of Osaka University), or Pparg cDNA and/or the pVSVG plasmid vector were used to transfect the retrovirus packaging cells, GP2-293 (Clontech Laboratories, Inc.). NIH3T3 or ST2 cells were infected with the pMX-puro vector expressing C/EBPs or PPARγ under the control of Moloney murine leukemia virus LTR, and cultured in the presence of Polybrene (8 μg/ml) for 1 day. Infected cells were cultured in the presence of 2 μg/ml of puromycin for 3 days. Transduced cells were further cultured to induce adipogenesis.

**Small Interfering RNA (siRNA)**—For transient silencing of C/EBPβ, ST2 cells were transfected with Silencer Select Pre-designed siRNA for C/EBPβ (s63860, Ambion, Invitrogen Corp.) with Lipofectamine RNAiMAX Reagent (Invitrogen), according to the manufacturer’s protocol. The siRNA
sequences were 5′-GGACCCUGCGGAACUUGUUtt-3′ for sense and 5′-AACAAGUUCCGCAGGGUGCtg-3′ for antisense. Silencer Select Negative Control (4390843, Ambion) was also transfected as a negative control. The transfected cells were cultured overnight and used for the experiments.

Flow Cytometry and Cell Purification by Magnetic Beads—Bone marrow cells were prepared from the femur and tibia of 2- to 15 month-old mice. Cells were stained with PE-conjugated anti-Pref-1 monoclonal antibody, FITC-conjugated anti-B220 monoclonal antibody, and/or biotin-anti-RANKL monoclonal antibody and streptavidin-APC. After washing, cells were analyzed using flow cytometry (FACSCalibur, BD Biosciences).

For purification of the RANKL-positive bone marrow cells, MACS Micro Beads were used according to the manufacturer’s protocol (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Mouse bone marrow cells were stained with PE-anti-RANKL monoclonal antibody (BioLegend) and anti-PE magnetic beads (Miltenyi Biotec), and RANKL-positive cells were purified using a MACS column and MACS Separator.

Luciferase Reporter Assay and Chromatin Immunoprecipitation (ChIP) Assay—A 708-bp fragment of the mouse Rankl (Tnfsf11) gene promoter region was amplified by using primers 5′-AACCTGAAGTAGCTTTTCCCTGACTGTT-3′ containing an XhoI site at the 5′ end and 5′-GGAAGCTTACCG-

![Figure 3](image_url)

**FIGURE 3. Increased osteoclastogenesis in adipogenic bone marrow cultures of aged mice.** A and B, after bone marrow cells from 4-month (4M)-, 1-year (1Y)-, and 2-year (2Y)-old mice were cultured for 10 days, the medium was switched to the adipogenic media with Dex/IBMX for an additional 13 days. Cells were stained with TRAP or H&E for CFU-osteoclast (CFU-OC) or CFU-fibroblast (CFU-F), respectively. The number of CFU-OC and CFU-F was counted, and data are shown as percentage of CFU-OC/CFU-F in each age group (B). The experiments were done twice in duplicate, and representative pictures are shown in A. *, p < 0.05; ***, p < 0.001. C and D, bone marrow cells from 1.5-year-old mice were cultured in the presence of the indicated concentrations of OPG in the adipogenic conditions and stained with either TRAP (for CFU-OC) or H&E (for CFU-F). The number of CFU-OC and CFU-F was counted, and data are expressed as percentage of CFU-OC/CFU-F (D). The experiments were done twice in triplicate, and representative pictures are shown C. n = 3 wells; ***, p < 0.001. Note that OPG inhibits osteoclast colony formation of bone marrow cells under adipogenic conditions. E and F, bone-resorbing activity determined by TRAP staining and pit assay. After bone marrow cells were cultured on dentin slices for 10 days, the medium was switched to the adipogenic media. As a reference, bone marrow macrophages were induced to differentiate into osteoclasts with RANKL (100 ng/ml) and M-CSF (100 ng/ml) on dentin slices. After 14 or 5 days of adipogenic condition (Aged BM cultures) or osteoclastogenic induction (RANKL + M-CSF), respectively, dentin was stained with TRAP for identification of osteoclasts and with Coomassie Brilliant Blue to visualize the resorption pits (E). Scale bar, 100 μm. The areas of osteoclast (OC) and resorption pits were quantified separately using NIH Image, and data are expressed as percentage of pit area/OC area (F). The experiments were done twice in five and six dentin slices for aged BM cultures and osteogenic induction, respectively. NS, not significant. G, bone marrow cells from 4-month-, 1-year-, and 2-year-old mice were cultured for 10 days as in A. After a change to the adipogenic media with Dex/IBMX, cells were cultured for 13 weeks. Medium were changed fresh every 3 days. Cells were stained with TRAP. Note that osteoclast colonies formed in the bone marrow cultures of aged mice under the adipogenic condition survived for 13 weeks.
GTTCACAGAGGTCTTGGC-3' containing a HindIII site at the 5' end. The PCR fragment was digested with Xhol and HindIII and cloned into a pGL3-basic luciferase reporter vector (Promega, Madison, WI). To construct deletion mutants of Rankl promoter vector, the following PCR primers were used: 5'-ATCTCGAGCACCCACCCCATTTTTC-3' for -556, 5'-ATCTCGAGCACCTTGGAGGAGTTCTAG-3' for -452, 5'-ATCTCGAGCTCTAAAGATTTTGAGAATG-3' for -345, 5'-ATCTCGAGGATTAGGCCCAGCCCTAGAG-3' for -241, 5'-ATCTCGAGGAAGCCTCCTCAGCAGAGGGC-3' for -192, 5'-ATCTCGAGGAAGGATAGGGGCCAG-3' for -138, and 5'-ATCTCGAGGAAGGATAGGGCCAGCCTAGAG-3' for -58. NIH3T3 cells were transfected with the Rankl promoter vector, according to the manufacturer's protocol. The Rankl-Luc reporter plasmids were co-transfected with Renilla-expressing control (pRL-CMV) (Promega) and C/EBPβ-reporter plasmids (pcDNA3.1(+), Invitrogen) or vector controls into NIH3T3 cells. Cell lysate was collected 48 h after transfection, and luciferase assays were performed using the Dual Luciferase Assay System (Promega). The intensity of luciferase activity was determined by a luminometer, and the reporter activity was calculated by normalizing the activity in the control. The expression of Rankl-Luc was determined by RT-PCR and normalized by GAPDH. The RT-PCR shown in the figure is representative of two independent experiments displaying similar results. B, induction of Rankl expression in stromal cell line ST2 following adipogenic stimulation. ST2 cells were cultured in the presence of Dex/IBMX, and RNA was extracted on the indicated days. The expression of Rankl, Opg, and Adipoq was determined by quantitative RT-PCR and normalized by Gapdh. n = 3 wells; **, p < 0.05; ***, p < 0.01; ****, p < 0.001. The RT-PCR shown in the figure is representative of two independent experiments displaying similar results. Note the induction of Rankl with the mirror-image suppression of Opg.

**RESULTS**

**Increased Rankl Expression and Adipogenesis with Aging**—In an attempt to address the link between osteoclastogenesis and the bone marrow adipocytes that develop during aging, we examined Rankl expression in bone marrow cells derived from young adult versus aged mice. As expected, reflecting increased adipose tissue in bone marrow with aging, aging was associated with an increased expression of adipocyte marker genes such as adiponectin (Adipoq), adipocyte P2 (Ap2), and PPARγ (Pparg), and concomitantly we found a 3-fold higher Rankl expression in the bone marrow of aged mice compared with younger mice (Fig. 1).

We then collected bone marrow cells from young adult (4 months old), middle aged (1 year old), and aged (2 years old) mice and cultured them under osteogenic or adipogenic conditions. The number of CFU-F, as determined by H&E staining, was significantly weaker than that of the osteoclasts generated under the stimulation of M-CSF and RANKL per cell basis (Fig. 2, A and B). In contrast, TRAP staining revealed a number of TRAP-positive colonies (CFU-OC) in cultures from aged mice under the same osteogenic conditions, whereas such colonies were rare or only occasionally seen in bone marrow cultures from young or middle aged mice, respectively (Fig. 2, A and B). It is to be noted that these cultures contained no exogenous osteoclastogenic cytokines or hormones, such as RANKL/M-CSF, 1,25-(OH)2D3, and parathyroid hormone. The osteoclast colonies formed under the osteogenic condition were completely inhibited by treatment with 100 ng/ml of OPG (Fig. 2, C and D), suggesting that it is RANKL dependent. When bone marrow cells from aged mice were cultured on dentin slices under the osteogenic condition, they displayed a bone-resorbing activity that was significantly weaker than that of the osteoclasts generated under the stimulation of M-CSF and RANKL per cell basis (Fig. 2, E and F).
RANKL as an Adipokine

When bone marrow cells were cultured under adipogenic conditions with Dex/IBMX, the frequency of osteoclast colony formation increased even more than under osteogenic culture conditions (Fig. 3, A and B). Again, the osteoclast colonies formed under the adipogenic condition was completely inhibited by treatment with OPG (Fig. 3, C and D), suggesting that it is RANKL dependent.

When bone marrow cells from aged mice were placed on dentin slices under the adipogenic condition, they formed numerous resorption pits (Fig. 3E) and displayed a potent bone-resorbing activity that was comparable with those generated under the stimulation of M-CSF and RANKL (Fig. 3F), indicating that they possess bone-resorbing activity. Osteoclasts generated *ex vivo* usually die within a couple of days, even if a potent survival factor, such as RANKL, is provided (19, 20). Surprisingly, osteoclast colonies formed in the bone marrow cultures of aged mice under adipogenic conditions survived more than 13 weeks without the addition of any stimulatory factors including RANKL (Fig. 3G). Thus, it is speculated that adipocyte-derived RANKL or some other factor promotes the survival as well as the development of osteoclast colonies.

Adipogenic Differentiation Induces Rankl Expression—To determine whether adipogenic differentiation induces an osteoclastogenesis-supporting microenvironment, primary marrow stromal cells were cultured under normal growth or adipogenic conditions with Dex/IBMX, and expression of Rankl, Opg (*Tnfrsf11b*), and *Adipoq* was assessed by quantitative RT-PCR. As shown in Fig. 4A, adipogenic cultures were associated with much higher expression of *Rankl* and concomitant suppression of *Opg*, in addition to a progressive increase in *Adipoq* expression. These data suggest that the induction of *Rankl* expression takes place, along with *Opg* down-regulation, on the way to adipocytic differentiation.

We further attempted to confirm the association of adipocytic differentiation with *Rankl* expression using the mouse bone marrow stromal cell line ST2. As shown in Fig. 4B, at baseline the *Rankl* mRNA level was low in ST2 cells, whereas *Opg* mRNA was abundantly expressed. When ST2 cells were induced to differentiate into adipocytes, *Rankl* expression was markedly increased, whereas *Opg* mRNA expression was progressively suppressed, along with the induction of *Adipoq* and *Ap2* expression (Fig. 4B).

Preadipocytic Cells in the Bone Marrow Express Rankl and Support Osteoclastogenesis—The transient induction of *Rankl* expression during adipogenesis and its decline upon full maturation suggest that *Rankl* expression is associated with preadipocytes. To test this *in vivo*, we characterized RANKL-positive cells in the bone marrow. In doing so, we collected preadipocytes by FACS using Pref-1 as the molecular marker for preadipocytes (21). As shown in Fig. 5A, flow cytometry revealed that the percentage of Pref-1 positive cells increased from 2 months (6.6%) to 12 months of age (11.1%). When bone marrow cells were gated according to the expression of Pref-1, it turned out that 28.2% of the Pref-1-positive population was clearly RANKL positive (R1 in Fig. 5B). Conversely, when bone marrow cells were gated according to the expression of RANKL and B220 (a marker for B lineage cells), most (83.55%) of the RANKL-positive and B220-positive cells were Pref-1 positive (R4 in Fig. 5)
Together, these data suggest a RANKL- and Pref-1-positive cell population exists in the bone marrow and is increased with aging.

We then purified these RANKL-positive bone marrow cells using anti-RANKL antibody and magnetic beads (Fig. 6). Again, the RANKL-positive cells purified in this manner were shown to express adipogenic marker genes, Adipoq, Ap2, and lipoprotein lipase (Lpl) mRNA was determined by quantitative RT-PCR and normalized with Gapdh. n = 3 wells; *, p < 0.05; **, p < 0.01; ***, p < 0.001. NS, not significant. The results shown are representative of two independent experiments displaying similar results. Note that the RANKL-positive cells from the aged (15M) mice exhibit a marked suppression of Opg expression. B and C, RANKL-positive bone marrow cells support osteoclastogenesis. RANKL-positive and negative bone marrow cells were collected from 6-month-old mice separately as in A, and co-cultured with bone marrow macrophages in the absence (None) or presence of Dex/IBMX for 5 days. Cells were then stained with TRAP (B), and the number of TRAP-positive multinucleated osteoclasts was counted (C). Data are expressed as the mean of 3 wells. ***, p < 0.001. The results shown are representative of two independent experiments displaying similar results.

**Induction of Rankl Transcription by C/EBPβ**—We finally examined the molecular mechanism by which Rankl expression is induced in the course of adipogenesis. During adipogenesis, a genetic program orchestrated by multiple transcription factors is evoked (22), and we focused on the early regulators C/EBPβ and C/EBPδ. When NIH3T3 fibroblasts, 3T3-L1 preadipocytes, or ST2 stromal cells were transduced with a retroviral vector containing C/EBPβ or C/EBPδ, Rankl expression was significantly increased compared to untransduced cells. These results suggest that C/EBPβ and C/EBPδ play important roles in the induction of Rankl expression during adipogenesis.
encoding C/EBPβ or C/EBPδ, Rankl mRNA expression was induced together with the adipocyte markers Pparg and Adipoq, as shown in Fig. 7, A–C, respectively. Furthermore, knockdown of C/EBPβ by siRNA abrogated the induction of Rankl mRNA by adipogenic culture (Fig. 7D). On the other hand, a PPARγ agonist TZD failed to induce Rankl expression in the preadipocyte cell line 3T3-L1, and stromal cell lines MC-3T3-G2/PA6 (PA6) and ST2, whereas these 3 cell lines express Pparg, and Rankl expression was induced under the adipogenic conditions of Dex/IBMX in PA6 and ST2 cells (Fig. 8A). Forced expression of PPARγ, even with TZD stimulation, failed to induce Rankl expression in NIH3T3 (Fig. 8B). Interestingly, a PPARγ antagonist BADGE slightly increased Rankl expression under the adipogenic conditions in 3T3-L1 and ST2 cells (Fig. 8C). Collectively the data suggest that C/EBPβ and C/EBPδ, transcription factors that act at an early stage in adipogenesis, transactivate Rankl gene expression.

To test the hypothesis that C/EBPβ or C/EBPδ binds to the Rankl promoter and transactivates the Rankl gene, a reporter assay was performed. As shown in Fig. 9A, when a C/EBPβ expression vector was co-transfected with a luciferase reporter vector that contains a 708-bp fragment of the 5′-flanking region of the mouse Rankl gene, luciferase activity was increased dose-dependently with the amount of the C/EBPβ expression plasmid.

**FIGURE 7.** Forced expression of C/EBPβ or C/EBPδ induces Rankl expression in NIH3T3, 3T3-L1, and ST2 cells. NIH3T3 (A), 3T3-L1 (B), or ST2 (C) cells were retrovirally transduced with either C/EBPβ or C/EBPδ, cultured for the indicated days and RNA was extracted. D, ST2 cells were transfected with either control or Cebpb siRNA, and transfected cells were cultured in the absence (Ctr) or presence (ADg) of Dex/IBMX, respectively, and RNA was extracted on day 2. Quantitative RT-PCR was performed for the expression of Rankl, Adipoq, Pparg, Opg, and Gapdh. Results are shown as mean ± S.D. of three separate transfections. *, p < 0.05; **, p < 0.01; ***, p < 0.001. NS, not significant. The RT-PCR shown in the figure is representative of at least two independent experiments displaying similar results.
mid in NIH3T3, C3H10T1/2, 3T3-L1, and ST2 cells. To narrow down a critical region for Rankl gene activation by C/EBP, a series of deletion mutants were constructed (Fig. 9B) and the reporter activity was determined. The results revealed that when the region from −192 to −138 was deleted, the response to C/EBP expression was abrogated, and that the region between −138 to −90 was required for the basal level of Rankl transcription (Fig. 9B). These data suggest that the region between −192 to −138 is important for RANKL gene activation by C/EBP.

ChIP assays with a specific antibody against C/EBP revealed that indeed a proximal region of the mouse Rankl gene promoter responsive to C/EBP expression was amplified specifically by using primers for the region between −216 to −140, when ST2 cells were treated with Dex/IBMX (Fig. 9C). These data are consistent with our concept that C/EBP and C/EBP bind to the Rankl promoter region, thereby transactivating Rankl gene expression.

DISCUSSION

With aging, bone loss occurs universally not only in humans but also in most animals including mice, and the C57BL/6 mouse strain is a widely accepted model of skeletal aging in which bone volume decreases with aging (23). It has also been reported that bone growth in C57BL/6 mice occurs during the first 3–4 months of life, and reaches a peak at around 5–6 months, followed by a gradual decline that continues throughout the lifespan. Bone loss in older mice is accompanied by an increase in the number of marrow adipocytes (24). Increased adiposity with aging has been studied mainly from the aspect of an imbalance between adipogenesis and osteoblastogenesis (11). As both adipocytes and osteoblasts are derived from mesenchymal stromal cells, it is reasonable to assume that increased adipogenesis is associated with a reciprocal suppression of osteogenesis (11). In fact, it was reported that haploinsufficiency of PPARγ, a key transcription factor for adipogenesis, promoted bone formation through enhanced osteoblastogenesis and suppression of adipogenesis, a mirror image of what occurs in the aging skeleton (25, 26).

With respect to the link between adipocytes and osteoclasts, several stromal cell lines have been shown to induce osteoclastogenesis (13–15). In the present study, we provide evidence for an osteoclastogenesis-supported ability not only in established stromal cell lines that were induced to differentiate into the adipocytic lineage, but also in primary stromal cells isolated from the bone marrow, especially when cultured under adipogenic conditions. Furthermore, we demonstrated the presence in the bone marrow in vivo of a RANKL- and Pref-1-positive cell population, i.e. RANKL-expressing preadipocytes. By ChIP assay we detected C/EBP binding in vivo to the 5‘-region of the Rankl gene between −193 to −138. This region contains a putative binding site of Sp1, which has been reported to interact with C/EBP (27).

Taken together with the fact that this region contains no consensus binding site for C/EBP, it is conceivable that C/EBP binds to this region indirectly via Sp1, thereby potentiating Rankl transcription. The fact that C/EBP and
C/EBPβ, which act at an early stage of the adipogenic program, but not PPARγ, which acts later at the final maturation stage, bind to the Rankl promoter and stimulate Rankl gene transcription, supports the contention that preadipocytes rather than mature adipocytes possess the ability to activate Rankl gene transcription, thereby supporting osteoclast development.

Rankl was first identified in T cells as a ligand of RANK on dendritic cells (28), and later found to be identical with the OPG ligand (29) or the osteoclast differentiation factor (30), which had been postulated to be present in osteoblastic/stromal cells (31). Rankl has also been identified in B cells (32) and a number of other cell types (33). Quite surprisingly, it has recently been reported that Rankl is most abundantly expressed in matrix-embedded osteocytes and that the Rankl produced by osteocytes is essential for bone resorption in vivo (33). However, how osteocytes deeply embedded inside bone come into contact with and present Rankl to osteoclast precursors in bone marrow remains an enigma. Adipocytes are surrounded in the bone marrow by hematopoietic cells, making it likely that they easily encounter osteoclast precursor cells of hematopoietic origin and thus are able to present Rankl as an osteoclastogenic signal. For example, leptin has been shown to inhibit osteoclastogenesis both in vitro (34) and in vivo (35), and because leptin treatment is associated with decreased fat mass in bone marrow (36), the reduced osteoclast generation may also be linked with reduced stimulation from adipocytes to hematopoietic osteoclast precursor cells within the marrow microenvironment. Although we showed that the increased number of Rankl-positive preadipocytes correlates with aging in vivo and that osteoclastogenic activity of bone marrow cell cultures ex vivo increases with the age of the animals, it remains to be clarified how much of the age-associated bone loss depends on Rankl derived from preadipocytes in the bone marrow. Quantitative assessment of the impact of specific Rankl deletion in bone marrow preadipocytes on age-related bone loss in vivo would be required to definitively answer this important question.

Attempts to develop in vitro methods that mimic the bone marrow microenvironment in vivo led to the invention of long term bone marrow cultures, represented by the Dexter-type culture for lymphopoiesis (37, 38) and the Whitlock-Witte culture for myelopoiesis (39). There has been no such long term culture system available for osteoclastogenesis that is effective in the absence of osteotrophic factors. To the best of our knowledge, the current study is the first to establish an in vitro culture system for osteoclast colony formation without the need of any exogenous bone-resorbing factors. We also found that osteoclast colonies are markedly increased in bone marrow cultures from aged mice, especially when they are induced toward adipogenic differentiation, and that they survived for several months. Although it is generally recognized that osteoblastogenesis decreases with aging, it has also been reported that CFU-F increases and CFU-Ob remains unaltered or even increases until 18 months old in mice (40, 41), implying that differences in culture conditions and the sex and age of animals used are important.

It has been reported that subcutaneous preadipocytes can trans-differentiate into bone-forming cells in the presence of certain factors (42), and adipocytes and osteoblasts may not be a fixed but rather a flexible phenotype. Thus, during the differentiation pathway from mesenchymal stem cells to adipocytes and osteoblasts, cells exhibit mixed molecular signatures. In the course of our analysis, we found that Pref-1- and Rankl-positive cells in the bone marrow also express B220, albeit weakly. Thus, these intermediate cells may acquire the potential to present Rankl and hence provide an osteoclastogenic microenvironment under certain circumstances, such as in the case of increased adiposity associated with aging, glucocorticoid excess, and other forms of metabolic dysfunction. In conclusion, the potential of bone marrow preadipocytes to express Rankl and support osteoclastogenesis may provide insight into the pathogenesis underlying the co-development of a fatty bone marrow and bone loss with aging.

REFERENCES

1. Rozman, C., Feliu, E., Berga, L., Reverter, J. C., Climent, C., and Ferrán, M. J. (1989) Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp. Hematol. 17, 34–37
2. Gimble, J. M., Robinson, C. E., Wu, X., and Kelly, K. A. (1996) The function of adipocytes in the bone marrow stroma: an update. Bone 19, 421–428
3. Justesen, J., Stenderup, K., Ebbesen, E. N., Mosekilde, L., Steineich, T., and Kassem, M. (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2, 165–171
4. Moore, S. G., and Dawson, K. L. (1990) Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. Radiology 175, 219–223
5. Duque, G. (2008) Bone and fat connection in aging bone. Curr. Opin. Rheumatol. 20, 429–434
6. Verma, S., Rajaratnam, J. H., Denton, J., Hoyland, J. A., and Byers, R. J. (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Clin. Pathol. 55, 693–698
7. Lee, W. S., Wronski, T. I., Morey, E. B., and Kimmel, D. B. (1983) Effects of spaceflight on trabecular bone in rats. Am. J. Physiol. 244, R310–R314
8. Kawai, K., Tamaki, A., and Hirohata, K. (1985) Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J. Bone Joint Surg. Am. 67, 755–763
9. Martin, R. B., Chow, B. D., and Lucas, P. A. (1990) Bone marrow fat content in relation to bone remodeling and serum chemistry in intact and ovariectomized dogs. Calcif. Tissue Int. 46, 189–194
10. Martin, R. B., and Zissimos, S. L. (1991) Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 12, 123–131
11. Rosen, C. J., and Bouxsein, M. L. (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2, 35–43
12. Bethel, M., Chiti, B. R., Sroug, E. F., and Kacena, M. A. (2013) The changing balance between osteoblastogenesis and adipogenesis in aging and its impact on hematopoiesis. Curr. Osteoporos. Rep. 11, 99–106
13. Benyahu, D., Peled, A., and Zipori, D. (1994) Myelocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Cell. Biochem. 56, 374–384
14. Kelly, K. A., Tanaka, S., Baron, R., and Gimble, J. M. (1998) Murine bone marrow stromally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro. Endocrinology 139, 2092–2101
15. Sakaguchi, K., Morita, I., and Murota, S. (2000) Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostaglandins Leukot. Essent. Fatty Acids 62, 319–327
16. Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., and Ikeda, K. (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5, 464–475
17. Takeshita, S., Arai, S., and Kudo, A. (2001) Identification and characterization of mouse bone marrow stromal cell lines immortalized by temperature-sensitive SV40 T antigen: supportive activity for osteoclast differen-
RANKL as an Adipokine

18. Takeshita, S., Kaji, K., and Kudo, A. (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1477–1488

19. Takeshita, S., Namba, N., Zhao, J. J., Jiang, Y., Genant, H. K., Silva, M. J., Brodt, M. D., Helgason, C. D., Kalesnikoff, J., Rauh, M. J., Humphries, R. K., Krystal, G., Teitelbaum, S. L., and Ross, F. P. (2002) SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat. Med. 8, 943–949

20. Nagase, Y., Iwasawa, M., Akiyama, T., Kadono, Y., Nakamura, M., Oshima, Y., Yasui, T., Matsumoto, T., Hirose, J., Nakamura, H., Miyamoto, T., Bouillet, P., Nakamura, K., and Tanaka, S. (2009) Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J. Biol. Chem. 284, 36659–36669

21. Smas, C. M., and Sul, H. S. (1993) Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 73, 725–734

22. Rosen, E. D. (2005) The transcriptional basis of adipocyte development. Prostaglandins Leukot. Essent. Fatty Acids 73, 31–34

23. Halloran, B. P., Ferguson, V. L., Simske, S. J., Burghardt, A., Venton, L. L., and Rosen, E. D. (2005) The transcriptional basis of adipocyte development. J. Bone Miner. Res. 20, 200–209

24. Takeshita, S., Kaji, K., and Kudo, A. (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1321–1329

25. O’Brien, C. A., Nakashima, T., and Takayanagi, H. (2013) Osteocyte control of osteoclastogenesis. Bone 54, 258–263

26. Holloway, W. R., Collier, F. M., Aitken, C. J., Myers, D. E., Hodge, J. M., Malakells, M., Gough, T. J., Collier, G. R., and Nicholson, G. C. (2002) Leptin inhibits osteoclast generation. J. Bone Miner. Res. 17, 200–209

27. Lecka-Czernik, B. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148, 2669–2680

28. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997) A homolog of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175–179

29. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombro, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176

30. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udaga, N., Takahashi, N., and Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95, 3597–3602

31. Suda, T., Takahashi, N., Udaga, N., Jimi, E., Gillespie, M. T., and Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345–357

32. Kanematsu, M., Sato, T., Takai, H., Watanabe, K., Ikeda, K., and Yamada, Y. (2000) Prostaglandin E2 induces expression of receptor activator of nuclear factor-κB ligand/osteoprotegerin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15, 1321–1329

33. O’Brien, C. A., Nakashima, T., and Takayanagi, H. (2013) Osteocyte control of osteoclastogenesis. Bone 54, 258–263

34. Holloway, W. R., Collier, F. M., Aitken, C. J., Myers, D. E., Hodge, J. M., Malakells, M., Gough, T. J., Collier, G. R., and Nicholson, G. C. (2002) Leptin inhibits osteoclast generation. J. Bone Miner. Res. 17, 200–209

35. Burguera, B., Hofbauer, L. C., Thomas, T., Gori, F., Evans, G. L., Khosla, S., Riggs, B. L., and Turner, R. T. (2001) Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142, 3546–3553

36. Hamrick, M. W., Della-Fera, M. A., Choi, Y. H., Pennington, C., Hartzell, D., and Baile, C. A. (2005) Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J. Bone Miner. Res. 20, 994–1001

37. Dexter, T. M., Wright, E. G., Krizsa, F., and Lajtha, L. G. (1977) Regulation of haemopoietic stem cell proliferation in long term bone marrow cultures. Biomedicine 27, 344–349

38. Dexter, T. M., Allen, T. D., and Lajtha, L. G. (1977) Conditions controlling the proliferation of haemopoietic stem cells in vitro. J. Cell. Physiol. 91, 335–344

39. Whitlock, C. A., and Witte, O. N. (1982) Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc. Natl. Acad. Sci. U.S.A. 79, 3608–3612

40. Zhang, W., Ou, G., Hamrick, M., Hill, W., Borke, J., Wenger, K., Chutkan, N., Yu, J., Mi, Q. S., Isales, C. M., and Shi, X. M. (2008) Age-related changes in the osteogenic differentiation potential of mouse bone marrow stromal cells. J. Bone Miner. Res. 23, 1118–1128

41. Shahnazari, M., Dwyer, D., Chu, V., Asuncion, F., Stolina, M., Ominsky, M., Kostenku, P., and Halloran, B. (2012) Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone 50, 628–637

42. Justesen, J., Pedersen, S. B., Stenderup, K., and Kassem, M. (2004) Subcutaneous adipocytes can differentiate into bone-forming cells in vitro and in vivo. Tissue Eng. 10, 381–391